Skip to main content
PLRX logo

PLRX

Pliant Therapeutics, Inc.
$1.11 -0.01 (-0.89%) At close · Jul 16
Market Cap
$71.21M
Shares
61,920,249

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue
$0
FY2025 Revenue FY2019–FY2025
Net Income
-$149.34M +29%
FY2025 Net Income FY2019–FY2025
Operating Margin
-11654.75% -10341.4pp
FY2023 Operating Margin FY2019–FY2023
Diluted EPS
-$2.43 +30%
FY2025 Diluted EPS FY2019–FY2025
Operating Cash Flow
-$128.34M +17.5%
FY2025 Operating Cash Flow FY2019–FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Line Item TTM FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019
$0 $0 $1.58M $9.69M $7.57M $41.82M $57.05M
$79.31M $109.16M $169.31M $127.8M $96.94M $77.55M $66.19M $47.35M
$39.91M $47.22M $59.06M $57.93M $39.95M $27.56M $17.27M $10.93M
$119.21M $156.37M $228.37M $185.73M $136.89M $105.11M $83.46M $58.28M
-$119.21M -$156.37M -$228.37M -$184.15M -$127.2M -$97.54M -$41.65M -$1.23M
-11654.75% -1313.37% -1288.1% -99.59% -2.16%
$1.76M $2.56M $3.02M $1.27M $791K $0
$478K $816K
-$366K -$216K
$0 $0 $0 $0 $0 $0 $0 $0
-$113.22M -$149.34M -$210.3M -$161.34M -$123.32M -$97.26M -$41.53M -$631K
-10211.14% -1273.32% -1284.51% -99.32% -1.11%
-$155.29M -$123.32M -$97.26M -$41.53M -$6.86M
-$113.72M -$149.68M -$210.33M -$159.03M -$125.08M -$97.43M -$41.56M -$632K
USD/shares -$2.43 -$3.47 -$2.75 -$2.94 -$2.71 -$1.95 -$4.22
USD/shares -$2.43 -$3.47 -$2.75 -$2.94 -$2.71 -$1.95 -$4.22
shares 61.37M 60.54M 58.72M 42.02M 35.85M 21.34M 1.62M
shares 61.37M 60.54M 58.72M 42.02M 35.85M 21.34M 1.62M
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue
Biotechnology median 8.53×
EV/EBIT
Biotechnology median 26.36×
P/E (TTM)
Biotechnology median 7.37×

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Reportable Segment $0 $0 $1,580,000 $9,685,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Reportable Segment -$156,373,000 -$228,365,000 -$184,145,000 -$127,200,000

Operating Margin by Segment (%)

Component 2023-12-31 2022-12-31
Reportable Segment -11654.7% -1313.4%
Key facts CIK 1746473 CUSIP 729139105 13F (30d) 3 filings 3 filers Visit website Investor relations